Melhem Solh

6.3k total citations · 1 hit paper
136 papers, 2.1k citations indexed

About

Melhem Solh is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Melhem Solh has authored 136 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Hematology, 62 papers in Oncology and 30 papers in Immunology. Recurrent topics in Melhem Solh's work include Hematopoietic Stem Cell Transplantation (56 papers), CAR-T cell therapy research (41 papers) and Acute Myeloid Leukemia Research (22 papers). Melhem Solh is often cited by papers focused on Hematopoietic Stem Cell Transplantation (56 papers), CAR-T cell therapy research (41 papers) and Acute Myeloid Leukemia Research (22 papers). Melhem Solh collaborates with scholars based in United States, United Kingdom and Italy. Melhem Solh's co-authors include Asad Bashey, Scott R. Solomon, Lawrence E. Morris, H. Kent Holland, Mehdi Hamadani, Brad S. Kahl, Kirit M. Ardeshna, Paolo F. Caimi, Carmelo Carlo‐Stella and Stacey Brown and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Melhem Solh

127 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

2021 264 citations Paolo F. Caimi, Weiyun Z. Ai et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Melhem Solh United States	26	1.2k	1.1k	586	529	308	136	2.1k
Muhıt Özcan Türkiye	21	944 0.8×	673 0.6×	319 0.5×	697 1.3×	360 1.2×	174	2.0k
Thomas J. Nevill Canada	25	761 0.7×	1.8k 1.6×	445 0.8×	422 0.8×	632 2.1×	99	2.5k
Eefke Petersen Netherlands	21	446 0.4×	924 0.9×	450 0.8×	270 0.5×	251 0.8×	69	1.7k
Noga Shem‐Tov Israel	23	584 0.5×	1.0k 1.0×	291 0.5×	241 0.5×	205 0.7×	85	1.7k
Stig Lenhoff Sweden	26	1.0k 0.9×	2.0k 1.8×	311 0.5×	244 0.5×	365 1.2×	87	2.7k
Ronit Yerushalmi Israel	24	772 0.7×	1.0k 1.0×	407 0.7×	193 0.4×	273 0.9×	105	1.9k
Richard Champlin United States	19	638 0.5×	1.1k 1.0×	251 0.4×	161 0.3×	191 0.6×	52	1.7k
Irena Sniecinski United States	22	510 0.4×	1.1k 1.0×	375 0.6×	339 0.6×	281 0.9×	49	1.8k
Ginna G. Laport United States	27	870 0.7×	1.2k 1.1×	996 1.7×	483 0.9×	255 0.8×	94	2.1k
Asad Bashey United States	32	1.4k 1.2×	2.6k 2.5×	1.2k 2.1×	308 0.6×	420 1.4×	162	3.5k

Countries citing papers authored by Melhem Solh

Since Specialization

Citations

This map shows the geographic impact of Melhem Solh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melhem Solh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melhem Solh more than expected).

Fields of papers citing papers by Melhem Solh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melhem Solh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melhem Solh. The network helps show where Melhem Solh may publish in the future.

Co-authorship network of co-authors of Melhem Solh

This figure shows the co-authorship network connecting the top 25 collaborators of Melhem Solh. A scholar is included among the top collaborators of Melhem Solh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melhem Solh. Melhem Solh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Malki, Monzr M. Al, Alla Keyzner, Yibin Chen, et al.. (2025). TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910). Transplantation and Cellular Therapy. 31(2). S59–S60.

Mercadal, Santiago, Kwang Woo Ahn, Praveen Ramakrishnan Geethakumari, et al.. (2024). Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy. Haematologica. 110(1). 218–221. 3 indexed citations

Baker, Steven Andrew, Asad Bashey, Lizamarie Bachier‐Rodriguez, et al.. (2024). Prophylactic Corticosteroids Allow Safe Outpatient Administration of Axicabtagene Ciloleucel with Comparable Toxicities to Other CAR-T Therapies in Large Cell Lymphoma. Blood. 144(Supplement 1). 2363–2363.

Daver, Naval, Abhishek Maiti, David A. Sallman, et al.. (2024). A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia (AMpLify).. Journal of Clinical Oncology. 42(16_suppl). TPS6586–TPS6586. 5 indexed citations

Malki, Monzr M. Al, Alla Keyzner, Hyung C. Suh, et al.. (2024). A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation.. Journal of Clinical Oncology. 42(16_suppl). TPS2678–TPS2678. 1 indexed citations

Solomon, Scott R., Lizamarie Bachier‐Rodriguez, Asad Bashey, et al.. (2024). Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based Transplantation. Transplantation and Cellular Therapy. 30(9). 903.e1–903.e9. 1 indexed citations

Bahlis, Nizar J., Caitlin Costello, Noopur Raje, et al.. (2023). Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nature Medicine. 29(10). 2570–2576. 76 indexed citations

Hamadani, Mehdi, Alexander I. Spira, Xiaolei Zhou, et al.. (2023). Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial. Blood Advances. 8(1). 93–98. 5 indexed citations

Solh, Melhem, Asad Bashey, H. Kent Holland, Lawrence E. Morris, & Scott R. Solomon. (2022). Allogeneic Hematopoietic Cell Transplantation (HCT) for Adult Patients with Acute Lymphoblastic Leukemia: Impact of Timely Transplantation on Survival Outcomes. Transplantation and Cellular Therapy. 28(3). S40–S40. 1 indexed citations

10.

Alderuccio, Juan Pablo, Weiyun Z. Ai, John Radford, et al.. (2022). Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood Advances. 6(16). 4736–4739. 1 indexed citations

11.

Solomon, Scott R., Michael T. Aubrey, Xu Zhang, et al.. (2022). Lineage-Specific Relapse Prediction After Haploidentical Transplantation With Post-Transplant Cyclophosphamide Based on Recipient HLA-B-Leader Genotype and HLA-C-Group KIR Ligand. Transplantation and Cellular Therapy. 28(9). 601.e1–601.e8. 9 indexed citations

12.

Solh, Melhem, Scott R. Solomon, Asad Bashey, et al.. (2022). Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD). Bone Marrow Transplantation. 58(2). 168–174. 3 indexed citations

13.

Patel, Krish, Jean‐Marie Michot, Asher Chanan‐Khan, et al.. (2021). Safety and Anti-Tumor Activity of Plamotamab (XmAb13676), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Subjects with Relapsed/Refractory Non-Hodgkin's Lymphoma. Blood. 138(Supplement 1). 2494–2494. 19 indexed citations

14.

Hamadani, Mehdi, John Radford, Carmelo Carlo‐Stella, et al.. (2020). Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 137(19). 2634–2645. 122 indexed citations

15.

Thapa, Bicky, Paolo F. Caimi, Kirit M. Ardeshna, et al.. (2020). CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy. Blood Advances. 4(16). 3850–3852. 47 indexed citations

16.

Kahl, Brad S., Mehdi Hamadani, John Radford, et al.. (2019). A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody–Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clinical Cancer Research. 25(23). 6986–6994. 77 indexed citations

17.

Goldberg, Aaron D., Martin S. Tallman, Melhem Solh, et al.. (2017). Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia. Blood. 130. 2662–2662. 8 indexed citations

18.

Kahl, Brad S., Mehdi Hamadani, Paolo F. Caimi, et al.. (2017). Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma. Blood. 130. 187–187. 6 indexed citations

19.

Solh, Melhem, et al.. (2011). Acquired Glanzmann's thrombasthenia with optimal response to rituximab therapy. American Journal of Hematology. 86(8). 715–716. 10 indexed citations

20.

Solh, Melhem, et al.. (2008). Quinine enhances the apoptotic and antiproliferative effects of Seocalcitol in breast cancer cell lines. Cancer Research. 68. 4028–4028. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact